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S U M M A R Y
Background: Clostridium difﬁcile infection (CDI) is increasingly being found in populations without
traditional risk factors. We compared the relative frequency, risk factors, severity, and outcomes of
community-onset CDI with hospital-acquired infection.
Methods: This was a retrospective, observational study of CDI at a tertiary hospital campus in Sydney,
Australia. Patients aged 15 years and older with a ﬁrst episode of CDI from January 1 to December 31,
2011 were included. CDI was deﬁned as the presence of diarrhoea with a positive enzyme immunoassay
in conjunction with a positive cell cytotoxicity assay, toxin culture, or organism culture. Main outcome
measures were onset of infection (hospital or community), risk factors, markers of severity, and
outcomes for the two groups.
Results: One hundred and twenty-nine cases of CDI infection were identiﬁed, of which 38 (29%) were
community-onset. The community-onset infection group were less likely to have a recent history of
antibiotic use (66% vs. 98%; p < 0.001) or proton pump inhibitor use (38% vs. 69%; p = 0.03) than the
hospital-acquired infection group. Markers of severity and outcomes were similar in the two groups,
with an overall mortality of 9%.
Conclusions: Community-onset CDI accounts for a large proportion of C. difﬁcile infections and has a
similar potential for severe disease as hospital-acquired infection. Using a history of previous antibiotic
use, proton pump inhibitor use, or recent hospitalization to predict cases is unreliable. We recommend
that patients with diarrhoea being investigated in emergency departments and community practice are
tested for Clostridium difﬁcile infection.
Crown Copyright  2014 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
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Clostridium difﬁcile infection (CDI) gained worldwide notoriety
after the severe outbreaks of colitis with associated mortality that
occurred in Canadian hospitals in 2003.1 Since that time, an
increase in incidence and disease severity has been seen globally,
with the emergence of the hypervirulent strain, PCR ribotype BI/
NAP1/027.2–4 More recently, new ribotypes associated with severe
disease have been identiﬁed.5 CDI has traditionally been seen in
older, hospitalized patients who have been exposed to antibiotics.2
Recently the literature has described CDI in populations without* Corresponding author. Tel.: +44 750 0781 247.
E-mail address: penepoly@hotmail.com (P. Clohessy).
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1201-9712/Crown Copyright  2014 Published by Elsevier Ltd on behalf of International 
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).these established risk factors, including community-onset infec-
tion without antibiotic use, and in peripartum women and
children.4,6–9 This study examined the frequency, severity, and
outcomes of community-onset CDI at a large hospital campus.
2. Methods
Episodes of CDI were identiﬁed retrospectively for the period
from January 1, 2011 to December 31, 2011 at a tertiary teaching
hospital campus in Sydney, Australia. Cases were identiﬁed by
searching the microbiology database for all positive enzyme
immunoassays (EIA) for C. difﬁcile glutamate dehydrogenase (GDH)
conﬁrmed with a positive cytotoxicity assay, toxigenic culture, or
organism culture. Samples were received at a single microbiology
laboratory from the public adult hospital, children’s hospital,Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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were processed in a standard manner with initial testing with the
EIA for C. difﬁcile GDH (PREMIER C. difﬁcile GDH; Meridian
Bioscience, Inc. Cincinnati, OH, USA), performed as per the
manufacturer’s instructions. GDH-positive samples were also
cultured on chromID C. difﬁcile agar (bioMe´rieux, Marcy l’Etoile,
France). Samples were directly inoculated as per the manufac-
turer’s instructions. Culture plates were incubated in an anaerobic
cabinet (MACS Anaerobic Workstation; Don Whitley Scientiﬁc Ltd,
Shipley, West Yorkshire, UK) at 37 8C. Culture plates were
examined at 24 and 48 h for any suspicious growth.
Suspect colonies were identiﬁed by matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS; Bruker Daltonik GmbH, Bremen, Germany). Suspected
colonies that failed to be identiﬁed by MALDI-TOF were identiﬁed
using a latex agglutination test (C. difﬁcile test kit DR1107A; Oxoid,
Basingstoke, Hampshire, UK). C. difﬁcile colonies were inoculated
onto pre-reduced cooked meat (Oxoid, Basingstoke, Hampshire,
UK) and incubated with a loosened lid for 48 h at 37 8C in an
anaerobic cabinet (MACS Anaerobic Workstation). An aliquot of
the supernatant was then ﬁltered through a sterile 0.2-mm syringe
ﬁlter (Whatman, Dassel, Germany). The cell cytotoxicity neutrali-
zation assay was performed with this sterile ﬁltrate. The
Clostridium difﬁcile Toxin/Antitoxin Kit (TechLab, Blacksburg, VA,
USA) and ‘Vero’ cells were used for the detection of C. difﬁcile toxin
B in the sterile ﬁltrate.10 Tests and the interpretation of results
were performed as per the manufacturer’s instructions.
Subjects aged 15 years and older were included. The hospital
infection control surveillance data were also reviewed to identify
missing cases. Cases were excluded if the stool sample was positive
by EIA alone without a positive C. difﬁcile culture and/or toxin
assays (faecal or organism). Only the ﬁrst episode was included for
each patient (thereby excluding cases of relapse or re-infection).
The isolates were not ribotyped.
The deﬁnitions used for CDI acquisition were consistent with
Australian and international guidelines.11–13 Community-onset
infection was deﬁned as symptom onset in the community OR a
positive stool culture within 72 hours (h) of admission, AND with
no hospital contact in the previous 12 weeks. Hospital acquisition
was deﬁned as a positive stool culture at >72 h after admission; OR
as symptom onset in the community OR a positive sample within
72 h of admission, AND with hospital contact in the previous
4 weeks. Indeterminate onset was deﬁned as symptom onset in the
community OR positive stool culture within 72 h of admission,
AND with recent hospital contact between 4 and 12 weeks.
Probable community-onset infection was a subgroup we deﬁnedTable 1
Risk factors, markers of severity, and outcomes of cases of hospital-acquired and comm
All 
n = 127 
Risk factors
Age, years, median (range) 69 (15–99) 
Age >60 years 84 (66%) 
Female 71 (56%) 
Previous antibiotics 97/109 (89%) 
Previous proton pump inhibitor 63/104 (61%) 
Markers of severity
White blood cell count 15  109/l 38/126 (30%) 
Creatinine 1.5  ULN 34 (27%) 
Albumin 25 mmol/l 43/119 (36%) 
Pseudomembrane on colonoscopy 4/14 (29%) 
Abnormal imaging 4/62 (6%) 
Outcome
30-day mortality 11 (9%) 
ULN, upper limit of normal.
a All data presented as n (%) unless stated otherwise. Indeterminate cases excluded as a positive stool culture between 72 and 120 h after admission in
a patient presenting with diarrhoea where no alternate diagnosis
was made AND with no hospital contact in the previous 12 weeks.
This subgroup was included in the community-onset group for
analysis.
Epidemiological information was obtained from the electronic
medical record (EMR) and included age, sex, and death within
30 days. The EMR was reviewed up to 6 months prior to the
positive stool culture to assess for antibiotic and proton pump
inhibitor use. This was done by reviewing triage and admission
notes, discharge summaries, operation reports, and electronic
medication lists.
Markers of severity included a white blood cell count (WBC)
15  109/L (normal 4.5–10  109/L), creatinine 1.5 times the
upper limit of normal or a glomerular inﬁltration rate (GFR)
reduced by 25% from baseline, and albumin 25 g/L (normal 32–
50 g/L). These parameters were chosen as they have been
identiﬁed previously as markers of severe infection in the
literature.11,13 The results were taken from the most abnormal
blood test within 48 h of the positive culture. Medical imaging was
reviewed that was performed within 5 days of any positive stool
culture, and included abdominal X-ray and abdominal computed
tomography (CT) or ultrasound scans. Toxic megacolon was
determined by the radiology report or ﬁndings of a large bowel
with a diameter greater than 7 cm. The presence of a pseudomem-
brane was determined by colonoscopy operative reports and
pathology ﬁndings.
We reviewed outcomes that were consistent with severe
infection, including new admission to the intensive care unit,
surgery, and death within 30 days.
The statistical analysis was undertaken using Microsoft Excel
2007. Signiﬁcance was set at p < 0.05 and was determined by two-
sample t-test for age and by Chi-square test for all other variables.
The study was approved by the Human Research Ethics Committee
(Northern Sector) of the South Eastern Sydney Local Health
District.
3. Results
One hundred and twenty-nine episodes of CDI were identiﬁed
from the microbiology database of which 89 (69%) were hospital-
acquired, 32 (25%) were community-onset, six (2.7%) were probable
community-onset, and two (1.5%) were indeterminate onset cases
(Table 1). The hospital infection control surveillance data did not
identify any additional cases. Fifty-eight cases were excluded fromunity-onset Clostridium difﬁcile infectiona
Hospital Community p-Value
n = 89 n = 38
73 (20–99) 61 (15–95) 0.10
61 (69%) 23 (61%) 0.86
48 (54%) 23 (61%) 0.93
78/80 (98%) 19/29 (66%) <0.001
52/75 (69%) 11/29 (38%) 0.03
25/88 (28%) 13 (34%) 0.94
20 (22%) 14 (37%) 0.42
36/83 (43%) 7/30 (23%) 0.29
1/4 (25%) 3/10 (30%)
0/38 (0%) 4/24 (17%) 0.08
7 (8%) 4 (11%) 0.97
(n = 2).
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toxin and culture results were negative.
There was a mild female predominance, which was more
prominent in the community-onset group (61% vs. 54%). The
overall median age was 69 years (range 15–99 years) and infection
was more commonly diagnosed in those older than 60 years of age.
Previous antibiotic use was found in 89% of all cases, with a much
higher rate found in the hospital-acquired group (98% vs. 66%,
p < 0.001). Proton pump inhibitors had been prescribed in 61% of
cases overall, also with a much higher rate in the hospital-acquired
group (69% vs. 38%, p = 0.03). The white cell count was reported in
99% of cases, creatinine was recorded in all cases, and serum
albumin in 94% of cases. The number of markers of severity per
case was similar in the two groups (Table 2).
Sixty-two patients had imaging performed and none had a toxic
megacolon. Four (17%) community-onset cases had other abnor-
malities detected, including dilated bowel and colitis. There were
no abnormalities on imaging in the hospital-acquired group.
Fourteen patients (11%) underwent colonoscopy, of whom four
(29%) had a pseudomembrane identiﬁed pathologically.
There was only one new admission to the intensive care unit
during this study and no patients required curative colectomy.
Overall there was a 9% all-cause mortality rate at 30 days, which
was not statistically different between the hospital-acquired and
community-onset cases (p = 0.08).
4. Discussion
This study identiﬁed that community-onset CDI presenting to a
Sydney teaching hospital campus is not uncommon and can be
severe. We found that 29% of cases were of community onset,
which is comparable to Australian and internationally reported
rates of 16–44%.4,5,7,14–16 New research from Australia has shown
the proportion of community-onset cases of CDI to have increased
signiﬁcantly in recent years, to 26%.16
The strong association with prior antibiotic use in hospital-
acquired CDI is not seen as commonly in the community-onset
group and cannot be relied upon to predict cases. Thirty-four
percent of community-onset cases did not have prior antibiotic use
as a risk factor, which is similar to the ﬁndings of other studies.1–
3,17 This has implications for community and emergency clinical
practice, as testing for CDI should be considered in people without
the traditional risk factors of hospitalization and antimicrobial
therapy. The burden of community-onset disease in our commu-
nity is likely to have been underestimated as we only captured
cases unwell enough to present to hospital and have a stool sample
collected.
Other studies have found community-onset cases to be more
likely in younger persons and females, and our data reﬂect this
ﬁnding; however the difference between groups did not reach
statistical signiﬁcance.6,7,14,17 Proton pump inhibitor use is a risk
factor for infection, as gastric acid suppression enables bacterial
survival and adhesion.8 Rates of proton pump inhibitor use in theTable 2
Number of abnormal markers of severity (white cell count elevation, altered renal
function, and hypoalbuminaemia) in community-onset and hospital-acquired cases
of Clostridium difﬁcile infectiona
No. of markers
of severity
All (n = 127) Hospital
(n = 89)
Community
(n = 38)
0 54 (43%) 37 (42%) 17 (45%)
1 39 (31%) 28 (31%) 11 (29%)
2 26 (20%) 19 (21%) 7 (18%)
3 8 (6%) 5 (6%) 3 (8%)
a x2 = 0.448; p-value = 0.80.community-onset group were similar to those reported in other
studies and this did not have as strong an association as was found
in the hospital acquisition group.17
Traditionally, community-onset CDI has been considered to be a
milder entity.15,18 We found the severity in the community-onset
group to be comparable to that in the hospital-acquired group as
judged by the proportion of cases with abnormal markers of severity,
cumulative numbers of markers per case, and clinical outcomes.
Other recent literature has drawn the same conclusion.2,9Of concern
is the 30-day all-cause mortality rate of 9%, with a trend towards
being higher in the community-onset group. This may suggest more
serious infection or may reﬂect earlier recognition in hospital-
acquired cases, and requires further study. The markers of severity
were only found in approximately 50% of cases who died within
30 days and it is important to note that serious disease may be
associated with normal laboratory ﬁndings at the time of diagnosis.
Imaging is infrequently abnormal and should only be used to look for
complications if there is a clinical suspicion.
Our study was limited by being a retrospective review of the
electronic medical record and may have been more complete by
reviewing the entire medical record. However, most variables and
outcomes could be assessed reliably in this manner.
In conclusion, community-onset CDI accounts for a large
proportion of C. difﬁcile infections and has a similar potential for
severe disease as hospital-acquired infection. Using a history of
previous antibiotic use, proton pump inhibitor use, or recent
hospitalization to predict cases is unreliable. We recommend that
patients with diarrhoea being investigated in emergency depart-
ments and community practice be tested for C. difﬁcile infection.
Conﬂict of interest: There are no conﬂicts of interest or funding to
disclose.
References
1. Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP. The emergence
of ‘hypervirulence’ in Clostridium difﬁcile. Int J Med Microbiol 2010;300:
387–95.
2. Bauer MP, Veenendaal D, Verhoef L, Bloembergen P, Van Dissel JT, Kuijper EJ,
et al. Clinical and microbiological characteristics of community-onset Clostridi-
um difﬁcile infection in the Netherlands. Clin Microbiol Infect 2009;15:1087–92.
3. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The
changing epidemiology of Clostridium difﬁcile infections. Clin Microbiol Rev
2010;23:529–49.
4. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difﬁcile infection
epidemiology. Clin Infect Dis 2012;55(Suppl 2):S65–70.
5. Bull AL, Worth LJ, Richards MJ. Implementation of standardised surveillance for
Clostridium difﬁcile infections in Australia: initial report from the Victorian
Healthcare Associated Infection Surveillance System. Intern Med J 2012;42:
715–8.
6. Fellmeth G, Yarlagadda S, Iyer S. Epidemiology of community-onset Clostridium
difﬁcile infection in a community in the South of England. J Infect Public Health
2010;3:118–23.
7. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of
and risk factors for community-associated Clostridium difﬁcile infection: a
nested case–control study. BMC Infect Dis 2011;11:194.
8. Quesada-Gomez C, Vargas P, Lopez-Urena D, Gamboa-Coronado Mdel M,
Rodriguez-Cavallini E. Community-acquired Clostridium difﬁcile NAP1/027-
associated diarrhea in an eighteen month old child. Anaerobe 2012;18:
581–3.
9. Tschudin-Sutter S, Tamma PD, Naegeli AN, Speck KA, Milstone AM, Perl TM,
et al. Distinguishing community-associated from hospital-associated Clostridi-
um difﬁcile infections in children: implications for public health surveillance.
Clin Infect Dis 2013;57:1665–72.
10. Donta ST, Shaffer SJ. Effects of Clostridium difﬁcile toxin on tissue-cultured cells.
J Infect Dis 1980;141:218–22.
11. Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, et al.
Australasian Society for Infectious Diseases guidelines for the diagnosis and
treatment of Clostridium difﬁcile infection. Med J Aust 2011;194:353–8.
12. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical
practice guidelines for Clostridium difﬁcile infection in adults: 2010 update by
the Society for Healthcare Epidemiology of America (SHEA) and the Infectious
Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:
431–55.
13. Implementation guide for surveillance of Clostridium difﬁcile infection 2013.
Australian Commission for Safety and Quality in Healthcare; 2013. Available at:
http://www.safetyandquality.gov.au/wpm-content/uploads/2012/02/1305-
P. Clohessy et al. / International Journal of Infectious Diseases 29 (2014) 152–155 155Implementation-Guide-CD_Word-Version-MAY-2013-TRIM-79212.doc
(accessed 2013–2014).
14. Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in
community-acquired Clostridium difﬁcile infection. Aliment Pharmacol Ther
2012;35:613–8.
15. Naggie S, Frederick J, Pien BC, Miller BA, Provenzale DT, Goldberg KC, et al.
Community-associated Clostridium difﬁcile infection: experience of a veteran
affairs medical center in southeastern USA. Infection 2010;38:297–300.16. Slimings C, Armstrong P, Beckingham WD, Bull AL, Hall L, Kennedy KJ, et al.
Increasing incidence of Clostridium difﬁcile infection, Australia, 2011–2012. Med
J Aust 2014;200:272–6.
17. Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of
community-acquired Clostridium difﬁcile-associated disease deﬁned by pre-
scription for oral vancomycin therapy. CMAJ 2006;175:745–8.
18. Jawa RS, Mercer DW. Clostridium difﬁcile-associated infection: a disease of
varying severity. Am J Surg 2012;204:836–42.
